Study details
Enrolling now
Lebrikizumab Trial for Atopic Dermatitis
Johann E Gudjonsson MD PhD
NCT IDNCT06906497ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
48
Study length
about 2.1 years
Ages
18+
Locations
2 sites in CA, MI
What this study is about
Researchers are testing a treatment called lebrikizumab for moderate-to-severe atopic dermatitis. The trial will collect health information and samples to see if the drug improves skin conditions over time.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take lebrikizumab
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
lebrikizumab
Endpoints
Secondary: Clinical response as assessed using the Peak Pruritus Numerical Rating Scale (NRS) (Pruitis NRS)
Body systems
Dermatology